Resources from the same session
Common themes in targeted therapy resistance across oncogene-driven NSCLC
Presenter: Sun Min Lim
Session: Best therapies with driver mutations in lung cancer
Resources:
Slides
Webcast
New targets, new drugs: Promising therapies for KRAS (including non-G12C mutations), HER2, NRG1 and other new targets
Presenter: Joop De Langen
Session: Best therapies with driver mutations in lung cancer
Resources:
Slides
Webcast
How can we optimise the use of immunotherapy for driver+ NSCLC: Are all targets the same?
Presenter: Tony S.K. Mok
Session: Best therapies with driver mutations in lung cancer
Resources:
Slides
Webcast
Q&A and discussion
Session: Best therapies with driver mutations in lung cancer
Resources:
Webcast